

### *Amendments to the Claims*

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (canceled)


2. (currently amended) A process for extracting 5-O-methyl-*myo*-inositol ~~a natural compound having antidiabetic effect extracted~~ from *Taxus spp*, said process comprising:

(a) extracting *Taxus spp* with an organic solvent to obtain an extractum,

(b) subjecting the extractum to a diphasic extraction,

(c) subjecting the water layers of said diphasic extraction to [[and a]] chromatography using a macroporous resin column, and collecting fractions containing 5-O-methyl-*myo*-inositol, then

(d) concentrating, crystallizing, and filtering ~~filtrating~~ to obtain a powder, recrystallizing the powder to obtain a second powder in which more than 90% of the second powder is said natural compound of 5-O-methyl-*myo*-inositol wherein said 5-O-methyl-*myo*-inositol has ~~having the~~ formula I:



wherein the organic solvent used for extraction is selected from ethanol, methanol, acetone, and aqueous mixtures thereof, and the solvent used for diphasic extraction is a water insoluble organic solvent.

3. (previously presented) The method according to claim 2, characterized in that said *Taxus spp* is *Taxus yunnanensis* Cheng et L. K. Fu, or *Taxus chinensis* var. *mairei* (Lemee et Levl) Cheng et L. K. Fu.

4. - 5. (canceled)


6. (previously presented) The method according to claim 2, characterized in that the solvent used for diphasic extraction is selected from ethyl acetate, chloroform, dichloromethane and ethyl ether.

7. (canceled)

8. (currently amended) The method according to claim 2, characterized in that the solvent system used for recrystallization ~~recrystallation~~ is a solvent system selected from ethanol, methanol, acetone, methylethylketone and a mixture thereof.

9. - 10. (canceled)

11. (currently amended) A method for treatment ~~and prevention~~ of a disease related to diabetes comprising administering to a patient in need thereof a medicament that contains extracted natural compound 5-O-methyl-*myo*-inositol having the formula I:



wherein said disease related to diabetes is selected from the group consisting of diabetic cardiovascular, cerebrovessel and glycometabolic disorder-associated diseases.


12. (currently amended) The method according to claim 11, characterized in that said medicament ~~is able to significantly alleviate~~ alleviates the hyperglycemia of diabetes, inhibits ~~inhibit~~ the decomposition of hepatic glycogen and the absorption of glucose, reduces the ~~reduce~~ blood fat level, ~~improve the metabolism of free radicals~~, and protects the ~~protect~~  $\beta$  cells of the pancreatic island in said patient.

13. (currently amended) The method according to claim 11, wherein said method ~~prevents and~~ treats complications from diabetic cardioangiopathy and other glycometabolic disorder-associated diseases in said patient.

14. (currently amended) The method according to claim 11, wherein said method ~~prevents and~~ treats type-II diabetes and complications in terms of diabetic cardioangiopathy in said patient.

15. (canceled)

16. (new) A method for prevention of a disease related to diabetes comprising administering to a patient in need thereof a medicament that contains extracted natural compound 5-O-methyl-*myo*-inositol having the formula I:



wherein said disease related to diabetes is selected from the group consisting of diabetic cardiovascular, cerebrovascular and glycometabolic disorder-associated diseases.

17. (new) The method according to claim 16, wherein said method prevents complications from diabetic cardioangiopathy and other glycometabolic disorder-associated diseases in said patient.

18. (new) The method according to claim 16, wherein said method prevents prevents type-II diabetes and complications in terms of diabetic cardioangiopathy in said patient.